METHODS: A systematic review that included full-length randomised controlled studies (RCTs), as well as post-hoc analyses of RCTs reporting new findings on myopia control treatments rebound effect in two databases, PubMed and Web of Science, was performed according to the PRISMA statement. The search period was between 15 June 2023 and 30 June 2023. The Cochrane risk of bias tool was used to analyse the quality of the selected studies.
RESULTS: A total of 11 studies were included in this systematic review. Unifying the rebound effects of all myopia control treatments, the mean rebound effect for axial length (AL) and spherical equivalent refraction (SER) were 0.10 ± 0.07 mm [-0.02 to 0.22] and -0.27 ± 0.2 D [-0.71 to -0.03] after 10.2 ± 7.4 months of washout, respectively. In addition, spectacles with highly aspherical lenslets or defocus incorporated multiple segments technology, soft multifocal contact lenses and orthokeratology showed lower rebound effects compared with atropine and low-level light therapy, with a mean rebound effect for AL and SER of 0.04 ± 0.04 mm [0 to 0.08] and -0.13 ± 0.07 D [-0.05 to -0.2], respectively.
CONCLUSIONS: It appears that the different treatments for myopia control produce a rebound effect after their cessation. Specifically, optical treatments seem to produce less rebound effect than pharmacological or light therapies. However, more studies are required to confirm these results.
方法:包括全长随机对照研究(RCT)的系统评价,以及对RCT的事后分析,报告了两个数据库中有关近视控制治疗反弹效应的新发现,PubMed和WebofScience,是根据PRISMA声明执行的。搜索期为2023年6月15日至2023年6月30日。使用Cochrane偏倚风险工具分析所选研究的质量。
结果:本系统综述共纳入11项研究。统一所有近视控制治疗的反弹效果,在10.2±7.4个月的冲洗后,轴向长度(AL)和球面等效折射(SER)的平均回弹效应为0.10±0.07mm[-0.02至0.22]和-0.27±0.2D[-0.71至-0.03],分别。此外,具有高度非球面透镜或散焦的眼镜结合了多段技术,与阿托品和低水平光疗相比,软性多焦点隐形眼镜和角膜塑形术显示出较低的回弹效应,AL和SER的平均回弹效应为0.04±0.04mm[0至0.08]和-0.13±0.07D[-0.05至-0.2],分别。
结论:似乎不同的近视控制治疗方法在停止后会产生反弹效应。具体来说,光学治疗似乎产生较少的反弹效果比药物或光疗。然而,需要更多的研究来证实这些结果。